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Abstract
Background: Smoking has long been positively associated with the development and progression of coronary heart
disease. However, longitudinal cohort studies evaluating smoking habits among cardiac patients as well as the role of
socio-demographic factors determining such behaviours are scarce and have been focused on primary care practice.
Thus the aim of the present work was to examine the association of active smoking and behaviours and exposure to
second-hand smoke, with the 10-year Acute Coronary Syndrome (ACS) prognosis, among cardiovascular patients.
Methods: From October 2003 to September 2004, a sample of six Greek hospitals was selected and almost
allconsecutive 2172 ACS patients were enrolled. In 2013–14, the 10-year follow-up was performed in 1918
participants (11 % loss to follow-up). Smoking habits at the time of entry to the study, as well as during the
follow-up period were studied using a standard questionnaire.
Results: Patients who had >60 pack-years of smoking had 57.8 % higher ACS mortality and 24.6 % higher risk for any
ACS event. Nested model, adjusted only for age and sex, revealed that for every 30 pack-years of smoking increase, the
associated ACS risk increased by 13 % (95 % CI 1.03, 1.30, p = 0.001). When further adjusted analysis, including several
potential confounders, was applied the tested relationship was still significant (95 %CI 1.03, 1.30, p= 0.09). Accordingly, the
risk for fatal ACS events increased by 8 % for every 30 pack-years of smoking increase (95 % CI 1.03, 1.63, p = 0.06).
Moreover, 52 % of the patients reported being exposed to secondhand smoke and when further adjustments were
made, it was revealed that they had 33 % (95 % CI 1.12, 1.60, p = 0.01) higher risk of having recurrent ACS events.
Conclusions: Active smoking and second-hand smoke among cardiac patients still represent a substantial clinical
burden. Thus, smoking cessation policies should be incorporated into the long-term therapeutic management.
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Background
The association between cigarette smoking and cardio-
vascular disease (CVD) has been explored since the early
‘60s, mainly in the Framingham Heart and the Seven
Countries studies [1, 2]. Hitherto, scientific evidence is
indisputable regarding the inverse effect of smoking,
both active and secondhand, on the cardiovascular sys-
tem [3, 4]. However, it seems that smoking cessation
recommendations cannot be successfully achieved and
cardiac patients, even shortly after hospital discharge,
adopt old habits regarding lifestyle behaviors (i.e. diet,
exercise, smoking) [5, 6]. Almost 26 % of ACS active
smoking patients, at time of hospital admission, contin-
ued smoking after 1 year of follow-up [7]. In the EURO-
ASPIRE II study, 21 % of the patients continued
smoking, after 3.5 years of follow-up [8]. Several factors
have been suggested as possible risk factors of failure in
smoking cessation (relapse) and low adherence to
healthy lifestyle habits, such as psychological stress, poor
social cognitive profile and lack of social support [9–11].
Considering the above factors, the achievement of smok-
ing cessation can be regarded as a complex and multidi-
mensional process.
In addition, exposure to second-hand smoke has been
documented to increase the risk of coronary heart dis-
ease by almost 30 % and moreover the risk increases ex-
ponentially with years of exposure [12–14]. Moreover, in
countries where smoke-free legislation has been strictly
implemented, they recorded 17 % declines in hospital
admissions for ACS events [15]. It has been documented
that smoke-free homes discourage smoking initiation
alongside with the encouragement of smoking cessation
[16].
Despite the large body of unequivocal evidence regard-
ing the role of both active smoking and second-hand
smoke in the involvement of atherosclerotic process, the
failure in smoking cessation among ACS patients re-
mains quite high and poses a growing disease burden.
Therefore, the aim of the present work, and under the
context of the GREECS (GREEk acute Coronary Syn-
drome) multi-center, longitudinal study [17], was to in-
vestigate the association between active smoking and
exposure to second-hand smoke and the 10-year risk for
fatal or non-fatal ACS events, among patients who had
had an acute cardiac event.
Methods
Sampling procedure at baseline examination 2003–2004
GREECS is a prospective, observational study that was
established in 2003. The main goal of the study was to
evaluate the annual incidence of ACS, as well as the role
of various CVD risk factors on the development and
prognosis of ACS. From October 2003 to September 2004,
n = 2172 consecutive patients with discharge diagnosis of
ACS (i.e., acute myocardial infarction (AMI) or unstable
angina (UA)) that were hospitalized in the cardiology
clinics or the emergency units of 6 major General Hospi-
tals in Greece (i.e., Hippokration hospital in Athens and
the general prefectural hospitals in Lamia, Karditsa, Halk-
ida, Kalamata and Zakynthos island) were enrolled into the
study (participation rate varied from 80 to 95 %). The hos-
pitals were selected in order to represent populations with
various socio-economic, cultural and regional character-
istics. Of the enrolled patients, n = 1649 (76 %) were
men (65 ± 13 years) and n = 523 (24 %) were women
(62 ± 11 years) (p for age and gender differences
<0.001). With the exception of Athens, where there
are several other hospitals, all the other hospitals
cover the whole population of the aforementioned re-
gions, including urban and rural areas. At entry, as
well as during hospitalization biomarkers suggesting
cardiac injury and AMI were measured. Moreover a
12-lead electrocardiogram (ECG) was performed and
clinical symptoms were evaluated in all patients, by a
cardiologist. AMI and UA were defined following the
up-to-date definitions [18, 19]. Medical information
was retrieved through hospital records.
Investigated measurements at baseline examination
The baseline examination included a variety of patients’
clinical, biochemical, socio-demographic and lifestyle
characteristics. Particularly, socio-demographic and life-
style characteristics included: age, sex, physical activity,
diet and smoking, years at school, financial and marital
status and psychological evaluation. In particular, as
regards smoking, patients were asked whether they were
current, former or never smokers. Current smokers were
defined as those who smoked at least 1 cigarette/day or
have attempted to quit smoking during the past
12 months, while the rest who smoked at some time
were defined as past or former smokers. The rest of the
patients were defined as never or occasional smokers
[20]. Questions about years of smoking exposure, type of
cigarettes smoked (i.e., light, heavy), number of ciga-
rettes/day, smoking at work or/and home place, were
asked; for the former smokers information about years
of smoking cessation was also recorded. Patients were
divided into four quartiles (statistically) according to the
distribution of the packs smoked per year: (a) 1st quartile
(0 pack/years), (b) 2nd quartile (<30 pack/years), (c) 3rd
quartile (30–60 pack/years) and (d) 4th quartile (>60
pack/years). The certain classification provided a better
distribution of the sample resulting in balanced sub-
groups. Special attention was also given to the baseline
exposure of second-hand smoke (in years), for at least
30 min per day, to cigarette smoke, at home, workplace,
as well as in indoor recreational environments. As
regards other major characteristics, financial status was
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classified – according to the Greek tax cut-offs - as:
“low” (<9000€), “moderate” (<18,000€), “good” (<48,000
€) and “very good” (>48,000€). Dietary habits were eval-
uated using a validated food frequency questionnaire
and the level of adherence to the Mediterranean dietary
pattern was assessed using the MedDietScore (range 0–55)
[21]. Higher values of this diet score indicate greater adher-
ence to the Mediterranean diet. Physical activity was evalu-
ated through a self-reported questionnaire provided by the
American College of Sports Medicine [22] and it was de-
fined as any engagement in activities of at least 3 times/
week and for at least 30 min. As regards medical history, it
was retrieved during the physical examination and through
the patient’s medical records and included the detailed as-
sessment of hypertension, hypercholesterolemia, diabetes
and any previous CVD event (i.e., prior to the baseline), as
well as the pharmaceutical treatment and management of
these conditions. Body mass index (BMI) was calculated as
weight (in Kg) divided by height (in m) squared. Obesity
was defined as BMI > 29.9 kg/m2.
Further details about the aims, measurements and
baseline procedures of the GREECS study may be found
elsewhere [17]
10-year follow-up evaluation
During 2013–2014, the 10-year follow-up of the pa-
tients was performed by the study’s investigators. In-
formation from n = 1918 of the initially enrolled
patients was retrieved; the remaining n = 254 patients
were lost after the 1st year of follow-up and consid-
ered as censored in the statistical analysis; no vital
status information at 10-year was available for these
patients (i.e., loss to follow-up around 11 %). Vital
status and development of ACS was evaluated using
WHO-ICD-9 coding (as it was also performed in the
30-day, 6-month and 1-year follow-up that has been
reported in previous publications) [17]. All patients
were interviewed by using a standard questionnaire.
Smoking during the 10-year follow-up period was also
assessed; for current smokers, number of cigarettes/
day and years of smoking were asked, while for the
former smokers information about the year of smok-
ing cessation was recorded. Moreover, exposure to
secondhand smoke was also obtained, following the
same methodology described above. Regarding pa-
tients who died within the decade and in order to
have an accurate death diagnosis, relevant information
was retrieved from the medical records, or local mor-
tality registries.
No differences were observed between those partici-
pated in the 10-year follow-up and those lost in
follow-up, in all baseline clinical and lifestyle factors
(all p’s >0.50).
Endpoints at follow-up
The endpoints studied in the 10-year follow-up were
recurrent fatal or non-fatal ACS events. In particular,
the development of a new AMI, angina pectoris,
other identified forms of ischemia (WHO-ICD coding
410–414.9, 427.2, 427.6), heart failure of different
types and chronic arrhythmias (WHO-ICD coding
400.0–404.9, 427.0–427.5, 427.9), were recorded by
the physicians of the study.
Bioethics
The study was approved by the Medical Research Ethics
Committee of the participating Institutions and was car-
ried out in accordance with the Declaration of Helsinki
(1989) of the World Medical Association. All patients
were informed about the aims and procedures of the
study and signed an informed consent.
Statistical analysis
Continuous variables are presented as mean values ±
standard deviation, while categorical variables are pre-
sented as absolute and relative (%) frequencies. Associa-
tions between normally distributed continuous variables
(i.e., MedDietScore, body mass index and age) and
groups of the patients per smoking quartile were evalu-
ated by the analysis of variance (ANOVA), after control-
ling for equality of variances (homoscedacity). Due to
multiple comparisons the Bonferroni rule was applied to
correct for the inflation of Type - I error. Years of school
variable that was abnormally distributed was tested
through Kruskal-Wallis. Associations between categor-
ical variables (i.e., sex, physical activity, financial status,
hypertension, hypercholesterolemia, diabetes mellitus,
family history of CVD) were tested by the use of the chi-
squared test. Survival curves according to quartiles of
pack-years of smoking were calculated and log-rank test
was implemented to evaluate median follow-up differ-
ences between quartiles. In order to control residual
confounding, which may exist between smoking and
ACS incidence, nested models were estimated. Thus, the
association between patients’ smoking (i.e., smoking sta-
tus estimated with pack-years and smoking cessation
after the baseline ACS or continue, within the decade)
and the dependent variable (i.e., 10-year ACS fatal/non
fatal events), after controlling for the above mentioned
potential confounders, was evaluated by the use of
nested Cox proportional hazard models. Proportionality
of the hazards was graphically tested by plotting the log
(-log(survival)) vs. the log- of survival time. First order
interactions between age, sex, medical history and smok-
ing were also evaluated for potential stratifying analyses.
Appropriate tests for goodness-of-fit (i.e., deviance and
Pearson’s residuals) were applied in order to evaluate the
robustness of the models’ estimates rather than create
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prediction models. Results are presented as hazard ratios
(HR) and their corresponding 95 % confidence intervals
(95 % CI). All statistical calculations were performed
with the SPSS version 21 software (IBM Hellas Inc,
Athens, Greece).
Results
Baseline characteristics by smoking among ACS patients
Of the enrolled patients, 34 % reported never smokers,
33 % reported active smokers and 33 % reported that
they have quit smoking for an average of 35 ± 39 pack-
years (median 30, 1st, 3rd quartile, 0 and 60, respect-
ively), at baseline examination. The vast majority of
smokers preferred smoking cigarettes (94 %) and the rest
tobacco or pipe. Of the non-smokers, 48 % reported ex-
posed to secondhand smoke at workplace or home, at
baseline examination. As it can be seen in Figure 1, pa-
tients in the 3rd and 4th upper quartiles of pack-years of
smoking had lower survival as compared with those in
the lower quartiles (p log-rank < 0.01); no difference was
observed between 3rd vs. 4th quartile (p = 0.78). More-
over, in Table 1 baseline factors that may act as con-
founders for the evaluation of smoking on 10-year ACS
incidence are presented. The analysis showed that pa-
tients who were active smokers at the time of first ad-
mission (baseline) and were in the upper quartile of
pack-years of smoking (i.e., >60) were more likely to be
younger age, mainly men, to report alcohol and coffee
consumption and to have a family history of CVD.
Moreover, patients in the lower quartile of pack-years of
smoking were more likely to have low/moderate income,
to be less educated, to report history of hypertension
and diabetes to be less physically active and to follow a
prudent diet close to the Mediterranean pattern.
Fatal or non-fatal ACS events during the 10-year
(2004–2014) of follow-up, by smoking among ACS
patients
The median ACS event free follow-up time was 8.3 years
for patients in the 1st quartile, 8.2 years for patients in the
2nd quartile, 8.1 years for patients in the 3rd quartile and
7.5 years for patients in the 4th of pack-years (p = 0.001).
Patients in the 4th quartile of pack-years of smoking had
57.8 % higher ACS mortality and 24.6 % higher risk for
any ACS event (Table 1).
In order to control residual confounding, nested
models were applied (Table 2). Age- and sex- only ad-
justed model revealed that for every 30 pack-years of
smoking increase the associated ACS risk increased by
13 % (model 1). Similarly, when, BMI, MedDietScore
and physical activity level, were included in the model as
potential confounders, the relationship between smoking
and the risk for ACS recurrent events remained signifi-
cant (Table 2, model 2). Additionally, when baseline co-
Figure 1 10-year survival curves for ACS* development, according to the quartiles of pack-years of smoking of the n= 2172 patients (log-rank p-values
between 4th, 3rd, and 2nd vs. 1st quartile <0.01, p-value between 4th vs. 3rd = 0.78). *ACS event: the development of a new acute myocardial infarction,
angina pectoris, other identified forms of ischemia, heart failure of different types and chronic arrhythmias during the 10 years follow-up time
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morbidities (i.e., history of hypertension, hypercholester-
olemia, diabetes and family history of CVD) were also
added in the analysis (Table 2, model 3), the tested rela-
tionship was still significant. No significant interactions
between baseline smoking and age, sex on the 10-year
outcome were observed (all p’s >0.50).
Further analysis was applied to evaluate the association
between exposure to secondhand smoke and 10-year oc-
currence of ACS fatal or non-fatal events. 52 % of the
non-smoker patients who had an ACS event during the
follow-up, reported that they were exposed to second-
hand smoke vs. 46 % of patients who did not have any
event (p = 0.01). No significant association was observed
when the analysis was focused only of fatal ACS events
(p = 0.45). When further adjustments were made for age,
gender, BMI, smoking status, MedDietScore, physical ac-
tivity, history of hypertension, hypercholesterolemia, dia-
betes and family history of CVD, it was revealed that
Table 1 Baseline demographic, lifestyle and clinical characteristics of the GREECS study participants, by quartiles of pack-years of
smoking (n = 2172)
Quartiles of pack-years
Baseline factors 1st 2nd 3rd 4th p
0 <30 30-60 >60
(n = 732) (n = 451) (n = 551) (n = 438)
Age (years),mean(SD) 72.0(11.4) 63.0(13.1) 62.7(13.0) 64.0(11.8) <0.001†
Men, % 43 88 95 93 <0.001
Years of school, mean(SD) 6.4(4.1) 8.7(4.4) 8.2(4.2) 8.3(4.3) <0.001††
Low/moderate financial status, % 72 62 69 65 0.01
MedDietScore (0–55), mean(SD) 28.6(5.4) 28.6(5.7) 28.4(5.5) 27.7(6.0) 0.02
Physical activity, % 31 46 41 42 <0.001
Obesity, % 27.5 27.4 27.7 27.7 0.53
Alcohol consumption% 11 32 31 31 <0.001
Cups of coffee/day 0.67 0.86 1.06 1.29 <0.001
History of hypertension, yes % 65 48 45 51 <0.001
History of diabetes, yes % 36 33 27 29 0.01
History of hypercholesterolemia, yes % 44 47 45 49 0.45
Family history of CVD, yes % 33 37 37 42 0.01
History of CVD (prior to baseline event), yes % 60 56 59 58 0.55
10-year follow-up data
ACS fatal events, % 12.1 16.0* 15.2* 19.1* 0.01┴
ACS events overall, % 36.1 33.0 41.0* 45.0* 0.001┴
p for trend between groups using: log-rank test (┴), Analysis of Variance (†) or non-parametric Kruskal-Wallis (††). *p < 0.05 for the comparisons between 2nd, 3rd,
4th vs. 1st quartile of pack-years (reference category), after correcting the probability of the inflation of type I error because of multiple comparisons, using the
Bonferroni rule (but, not accounting for age differences)
Table 2 Results from nested Cox proportional hazards models regarding the association between pack-years of smoking and 10-year
ACS fatal or non-fatal event among cardiac patients (n = 2172)
Models for any ACS event Hazard
Ratio
95 % CI p Model adjusted for:
Model 1: per 30 cigarette pack/years 1.13 1.03,1.30 0.001 Age, gender
Model 2: per 30 cigarette pack/years 1.09 1.03,1.30 0.01 Age, gender, obesity, MedDietScore, physical activity
Model 3: per 30 cigarette pack/years 1.06 1.03,1.30 0.09 Model 2 plus history of hypertension, hypercholesterolemia, diabetes and
family history of CVD




0.06 Factors used in Model 3
Cox regression models were applied with the 10-year ACS event as dependent variable and potential confounders gradually adjusted in the models as follows:
Model 1: age, gender; Model 2: age, gender, Body Mass Index, MedDietScore, physical activity; Model 3: age, gender, Body Mass Index, MedDietScore, physical
activity, history of hypertension, hypercholesterolemia and diabetes mellitus, family history of CVD; Cox regression model was also applied with the 10-year ACS
mortality as dependent variable and the following confounders as adjusting factors: age, gender, Body Mass Index, MedDietScore, physical activity, history of
hypertension, hypercholesterolemia and diabetes mellitus, family history of CVD
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patients who reported exposure to secondhand cigarette
smoke, at workplace, at home or other places had 33 %
higher risk of having a fatal or non-fatal ACS event and
27 % higher risk for a fatal event (Table 3). When the
analysis was focused on the source of exposure, no sig-
nificant results were observed (probably because of the
lack of sufficient data).
Discussion
The present study is one of the very few cohort studies
that have investigated active smoking as well as exposure
to second-hand smoke, within the 10-year of follow-up,
among ACS patients. It was documented that patients
who were current smokers and reported smoking for al-
most 60 pack-years at baseline examination were more
likely to be men, of younger age, to have higher alcohol
and coffee consumption and have a family history of
CVD, as compared with patients in the lower quartile of
pack-years of smoking. It was of interest that non-
smokers, at baseline examination, were less educated,
were in the low/moderate financial group, were less
physically active and followed a diet close to the Medi-
terranean pattern; however, all these associations may be
attributed, at least partially, to baseline age differences
between smoking groups. Nevertheless, as regards finan-
cial status it has been documented that financial crises
lead to reduction in smoking prevalence due to reduced
affordability of cigarettes [23, 24]. Even though, the vast
majority of data support the relationship between educa-
tional level and smoking prevalence, our findings are in
accordance with the results from nine European coun-
tries examining the trends of smoking habits by educa-
tion group. They observed that smoking declines were
higher among the least educated participants, probably
attributed to smoking cessation policies such as, free or
subsidized access to smoking cessation therapies, tele-
phone help lines, bans on tobacco advertisements, pri-
cing policies [25].
It was also found that patients who, at baseline exam-
ination, reported more than 60 pack-years of smoking
had 57.8 % higher risk of fatal ACS event and 24.6 %
higher risk for any ACS event during the decade, as
compared with patients who reported non-smokers; this
effect was confirmed even when further adjustments
were made. Similarly, even when patients smoked fewer
pack-years (i.e. <30 and 30–60 pack-years) the risk
remained significantly higher as compared with patients
who reported non-smokers. Multivariable analysis, after
adjusting for age, sex, as well as BMI, MedDietScore,
physical activity level and clinical characteristics (i.e.,
history of hypertension, hypercholesterolemia, diabetes
and family history of CVD), revealed that for every 30
pack-years of smoking increase, the risk for ACS recur-
rent events was significantly high. Smoking still consti-
tutes a major risk factor for ACS. The Updated Report
2014 of the American Heart Association documented
that, regardless the declining rates of smoking since
1998, almost 20.5 % of men and 16 % of women remain
current smokers. Regarding health care costs, in 2010
ACS and stroke accounted for 15 % of total health costs,
while indirect costs are estimated to increase by 58 % in
2030 [26]. However, previous studies have suggested the
“smoker’s paradox” among post-myocardial infarction
(MI) patients, in a way that smokers may have a better
disease prognosis compared with non-smokers [27, 28].
Nevertheless, the certain phenomenon is likely to be at-
tributed to differences in patients’ socio-demographic
characteristics, in different medical treatment plans and
mainly to the fact that it was observed only in short-
term outcomes [29].
Even though, quit smoking was not analysed in this
work - due to some methodological limitations -, it is
well documented in the scientific literature that smoking
cessation among cardiac patients contributes substan-
tially to the reduction in CVD death rate by almost 40 %
[25, 30]. Accordingly, a systematic review of cohort stud-
ies resulted in a significant reduction in ACS mortality
rate as well as in rehospitalisation for MI, among cardiac
patients [31]. However, regardless of the scientific evi-
dence about the benefits of quitting smoking on ACS
prognosis, there are equally strong indications that car-
diac patients fail to discontinue smoking even immedi-
ately after hospital discharge [32, 33].
As regards second-hand smoke, it was revealed that
exposure at home or in indoor recreational activities
(i.e., pubs, bars, restaurants, etc) was positively associ-
ated with the 10-year fatal or non-fatal ACS events,
while an inverse association was observed with exposure
to tobacco smoke at workplace. Α possible explanations
to the aforementioned result could be that most of the
patients were retired and had no additional risk deriving
from their exposure at work. A meta-analysis study
Table 3 Results from nested Cox proportional hazards models
regarding the association between exposure to secondhand
cigarette smoke and 10-year ACS fatal or non-fatal events,
among cardiac patients (n = 2172)
Models for any ACS event Hazard Ratio 95 % CI p
Exposed vs. non-exposed 1.33 1.12, 1.60 0.01
Exposed at workplace vs. non-exposed 0.96 0.78, 1.20 0.69
Exposed at home vs. non-exposed 1.13 0.89, 1.43 0.30
Models for fatal ACS event
Exposed vs. non-exposed 1.27 1.01, 1.60 0.05
Exposed at workplace vs. non-exposed 0.87 0.66, 1.14 0.31
Exposed at home vs. non-exposed 1.21 0.99, 1.70 0.25
All models were adjusted for age, gender, BMI, smoking status, MedDietScore,
physical activity, history of hypertension, hypercholesterolemia, diabetes and
family history of CVD
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documented that in public locations where comprehen-
sive smoke-free legislation is implemented, the reduction
in hospitalizations for ACS reached almost 14 % com-
pared to 8 % in locations with partial smoke-free legisla-
tion [34]. Second-hand smoke remains one of the main
CVD risk factors, in the same level like active cigarette
smoking [35]. In the United States, almost 33.951 of
cigarette smoking–related CVD deaths are attributable
to secondhand smoke, each year [36]. The possible
mechanism through which secondhand smoke is closely
related to increased risk of ACS morbidity and mortality
is the same to that of active smoking i.e. acceleration of
atherosclerosis due to damage of the endothelial lining
as well as increased concentration of inflammatory
markers [37, 38]. Finally, recent studies have indicated
the harmful effects on CVD risk not only of second-
hand smoke at home (from spouses/cohabitants) but
also the residual tobacco smoke toxic substances long
after a cigarette is extinguished (“third-hand smoke” haz-
ards), advocating a rigorous enforcement of smoke-free
home policies [39–41].
Several trials have provided results on the effectiveness
of cessation counselling and rehabilitation programs
based on both behavioural and medication therapy (i.e.
Nicotine Replacement Treatment (NRT), bupropion and
varenicline) [42–44]. However, the nature of such inter-
ventions should be tailored-made according to the dis-
ease severity and the patients’ co-morbidities [45].
Limitations
The present study has some limitations. Recall bias may
exist, especially regarding the evaluation of exposure to
secondhand smoke. Additionally, social desirability may
influence patients’ answers. Smoking status was assessed
through self-reporting statement, which might under- or
over-estimate the actual behaviour, but this type of data
collection is the frequently applied in observational stud-
ies [46, 47]. Information regarding the exact date of quit-
ting was not assessed due to the uncertainty of the
information provided; thus, it may be hypothesized that
some of the patients may have quitted smoking after the
new ACS event, and therefore they could be considered
as quitters in the present analysis. Smoking among pa-
tients was measured at the baseline examination, as well
as at the end of the 10-year follow-up therefore they
may be prone to life-course changes during the decade
and, consequently influence the robustness of the find-
ings. Another limitation could be the fact that the rea-
sons leading patients to quit or continue smoking were
not explored since the main purpose of the study was to
investigate the association between active smoking and
exposure to second-hand smoke and the 10-year risk for
fatal or non-fatal ACS events.
Conclusion
The present study highlighted a crucial issue about
current smoking behaviours among cardiac patients,
with both active smoking and secondhand smoke play-
ing a detrimental role in the 10-year ACS incidence and
mortality. Smoking cessation appeared to reduce the risk
of recurrent ACS events by almost half, within the dec-
ade. Respectively, exposure to secondhand smoke repre-
sented a substantial risk factor in the disease prognosis,
with 3 out of 10 patients exhibiting ACS recurrent
events (fatal or non-fatal). Intervention strategies regard-
ing smoking cessation and reduced exposure to environ-
mental smoke should be targeted towards cardiac
patients in order to further eliminate the disease burden.
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